Viral Vector Manufacturing Facility Pty Ltd (VVMF) is set to participate in BIO KOREA 2025, May 7-9 2025, bringing its expertise in viral vector manufacturing to one of Asia’s premier biotechnology conventions.
Representing VVMF at this event, Anita van der Meer, Head of Business Development and Partnerships, will be available at the Australian Pavilion for meetings and discussions.
“We are excited to engage with global industry professionals at BIO KOREA 2025 and share VVMF’s advanced capabilities in recombinant lentiviral (rLV) and recombinant adeno-associated viral (rAAV) vector process development and manufacturing” said Anita van der Meer.
VVMF is committed to supporting biotech and pharmaceutical companies by providing high-quality viral vector solutions tailored to their research, clinical, and commercial needs. With access to leading scientific and clinical expertise, VVMF offers a strategic advantage, further strengthened by Australia’s 43.5% R&D tax incentive for eligible companies.
Schedule a meeting through the one-on-one partnering platform on the BIO KOREA website or contact us at info@vvmf.com.au to explore how VVMF can be your trusted partner in advancing cell and gene therapies.
Unlocking the future of medicine – with you at BIO KOREA.